Michael A. White
President of Research & DevelopmentDr. Michael A. White, Ph.D., also known as Mike, had been the Chief Scientific Officer at IDEAYA Biosciences, Inc. since October 2021 until September 28, 2026 and is President of Research and Development since September 28, 2026 and served as its Senior Vice President until 2023. He served as Member of Scientific Advisory Board at Biosplice Therapeutics, Inc. Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc. Dr. White served as a Chief Scientific Officer at Biosplice Therapeutics, Inc. since April 2020 until October 2021. Prior to joining Pfizer, Dr. White had a prolific over twenty-year academic career at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program. In 2015, Dr. White received the inaugural Outstanding Investigator's Award from the National Cancer Institute (NCI), the U.S. Government's principal agency for cancer research and has authored over 150 publications with over 30,000 citations. Dr. White is a discovery biologist with two decades of R&D leadership experience in industry and academia. He has deep expertise in cell regulation, tissue homeostasis, tumor biology, therapeutic target discovery, technology development and drug discovery. There he led a cross-disciplinary group to build an oncology small-molecule pipeline focused on first-in-class therapies that intercept oncogenic signaling networks, modulate tumor/host interactions and promote productive anti-tumor immune responses. These efforts culminated in numerous INDs within the past few years. Previously, Dr. White held positions of Professor of Cell Biology at UT Southwestern Medical Center, Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center and inaugural Director of the UTSW Cancer Intervention and Prevention Discovery training program. His appointments include the Hortense and Morton Sanger Professorship in Oncology, the Sherry Wigley Crow Cancer Research Endowed Chair and the Grant A. Dove Distinguished Chair for Research in Oncology. In 2015, Dr. White received the inaugural National Institute of Cancer’s Outstanding Investigator Award. Dr. White’s research has focused on oncogenic Ras effector networks, the molecular architecture of mitogenic signaling pathways, functional annotation of cancer genomes and genomics-guided cancer target discovery. He has authored over 150 publications with over 22,000 citations. Dr. White completed his postdoctoral training in cancer biology and signal transduction at Cold Spring Harbor Laboratories in New York. Previously, Dr. White held positions of Professor of Cell Biology at UT Southwestern Medical Center, Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center and inaugural Director of the UTSW Cancer Intervention and Prevention Discovery training program. He received his PhD in Biology from the University of North Carolina at Chapel Hill and his BS in Zoology from University of Iowa.
Positions
- Company NameIDEAYA Biosciences, Inc.Stock CodeIDYAPositionPresident of Research & DevelopmentColleagues
- YSYujiro S. HataFounder, President, CEO & Chairman
- JBJoshua BleharskiChief Financial Officer
- ARAndres Ruiz BrisenoChief Accounting Officer
- DBDouglas B. SnyderChief Legal Officer
- JLJeffrey L. SteinIndependent Director
- SWScott William MorrisonIndependent Director
- FPFrank P. McCormickChair of Scientific Advisory Board
- TJTerry J. RosenLead Independent Director
